Last updated on April 16, 2014 at 21:24 EDT

Latest XBiotech Inc. Stories

2012-12-12 12:25:51

AUSTIN, Texas, Dec. 12, 2012 /PRNewswire/ -- XBiotech Inc., a privately held biotechnology company, today announced positive Phase II clinical trial results in the treatment of acne vulgaris. The trial was conducted as an open label study using XBiotech's lead candidate, True Human(TM) monoclonal antibody MABp1, in patients with moderate to severe disease. Patients enrolled in the study demonstrated continual improvement in lesions over the course of therapy, with up to 42 percent reduction...

2011-06-02 11:04:00

MORRISTOWN, N.J., June 2, 2011 /PRNewswire/ -- C3i, a world leader in clinical trial support services, today announced the signing of its newest client, XBiotech, Inc. XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer,...